DFTX
HEALTHCAREDefinium Therapeutics Inc
$23.42+1.02 (+4.55%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving DFTX Today?
No stock-specific AI insight has been generated for DFTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$6.03$26.25
$23.42
Fundamentals
Market Cap$2.6B
P/E Ratio—
EPS$-2.06
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume1.5M
Avg Volume (10D)—
Shares Outstanding109.1M
DFTX News
21 articles- Definium Therapeutics (DFTX) Deepens Losses Advancing Psychedelic Pipeline Is Its Cash Strategy Still Coherent?Yahoo Finance·May 9, 2026
- Definium Therapeutics Q1 Earnings Call HighlightsMarketbeat·May 8, 2026
- Definium (DFTX) Q1 2026 Earnings TranscriptMotley Fool·May 7, 2026
- Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent HighlightsYahoo Finance·May 7, 2026
- A Look At Definium Therapeutics (DFTX) Valuation As DT120 ODT Nears Key Phase 2 And Phase 3 ReadoutsYahoo Finance·May 4, 2026
- Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026Yahoo Finance·Apr 30, 2026
- These 3 Psychedelic Stocks Activated After Trump’s Executive OrderInvesting.com·Apr 27, 2026
- These 3 Psychedelic Stocks Activated After Trump's Executive OrderMarketbeat·Apr 27, 2026
- Definium Therapeutics Investor Day: DT120 Phase III Readouts Set for Late Q2–Q3, PTSD Plan for 2027Marketbeat·Apr 24, 2026
- Psychedelic Pharma Stocks Are Riding High. Past Cannabis Returns Are a Reality Check.Yahoo Finance·Apr 24, 2026
- FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers GainYahoo Finance·Apr 24, 2026
- The Bull Case For Definium Therapeutics (DFTX) Could Change Following US Psychedelic Policy MomentumYahoo Finance·Apr 23, 2026
- Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst DayYahoo Finance·Apr 22, 2026
- How Trump Sent Psychedelics-Tied Compass Pathways And Others FlyingYahoo Finance·Apr 20, 2026
- Definium Therapeutics Announces New Employee Inducement GrantsYahoo Finance·Apr 20, 2026
- Market Minute 4-20-26- Oil Pops, Stocks Slide on Fading Peace HopesYahoo Finance·Apr 20, 2026
- Psychedelic Shares Rise Following Trump's Executive Order to Accelerate Treatments for Serious Mental IllnessYahoo Finance·Apr 20, 2026
- Psychedelic stocks soar after Trump signs executive order to fast-track treatmentsYahoo Finance·Apr 20, 2026
- Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical TreatmentsYahoo Finance·Apr 18, 2026
- Is It Too Late To Consider Definium Therapeutics (DFTX) After Its Strong 1 Year Run?Yahoo Finance·Apr 18, 2026
- Trump Trade: President to sign order on psychedelic used for PTSDYahoo Finance·Apr 17, 2026
All 21 articles loaded
Price Data
Open$22.46
Previous Close$22.40
Day High$23.53
Day Low$22.46
52 Week High$26.25
52 Week Low$6.03
52-Week Range
$6.03$26.25
$23.42
Fundamentals
Market Cap$2.6B
P/E Ratio—
EPS$-2.06
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume1.5M
Avg Volume (10D)—
Shares Outstanding109.1M
About Definium Therapeutics Inc
Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company is headquartered in New York, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—